In the Indian pharmaceutical industry, there were 17 M&A deals announced in Q2 2023, worth a total value of $287.2m, according to GlobalData’s Deals Database. The $126.1m minority acquisition of unichem laboratories by ipca laboratories was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes, the M&A activity and most notable deals are included in GlobalData’s Pharma Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, M&A activity in India decreased by 57% in Q2 2023 compared with the previous quarter’s total of $669.7m and fell by 54% as compared to Q2 2022. Related deal volume decreased by 15% in Q2 2023 versus the previous quarter and was 13% higher than in Q2 2022.
The top-ranked financial advisors supporting these M&A deals in India in Q2 2023 were Avendus Capital; Spark Capital; Stifel Financial with 1, 1, 1 deals respectively.
The top-ranked legal advisorss supporting these M&A deals in India Q2 2023 were Khaitan & Co; Cyril Amarchand Mangaldas; DSK Legal with 3, 1, 1 deals respectively.
For further understanding of GlobalData's Pharma Industry Mergers and Acquisitions Deals by Top Themes, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.